AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 22318278
Drug: 4CMenB at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4CMenB at 2, 4, and 6 months with routine vaccines
Trial: 22318278
Drug: 4CMenB at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4CMenB at 2, 4, and 6 months without routine vaccines
Trial: 22318278
Drug: 4CMenB with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4CMenB with routine vaccines at 2, 3, and 4 months
Trial: 22318278
Drug: Routine vaccines
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine vaccines alone at 2, 3, and 4 months
Trial: 22318278
Drug: 4CMenB doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4CMenB doses administered alone
Trial: 22318278
Drug: Routine vaccines
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine vaccines given alone
Trial: 22318278
Drug: 4CMenB and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4CMenB and routine vaccines administered together
Trial: 20705156
Drug: 200 mcg
RxNorm normalized name: CrM 200 MCG Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mcg misoprostol
Trial: 20705156
Drug: 400 mcg
RxNorm normalized name: Biotin 400 MCG Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mcg misoprostol
Trial: 17337887
Drug: ASA +
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ASA + extended-release dipyridamole (DP)
Trial: 9523035
Drug: High vitamin
RxNorm normalized name: Super High Vitamins and Minerals
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High vitamin E supplements
Trial: 15485475
Drug: Oral methionine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral methionine, 100 mg kg(‐1) in fruit juice
Trial: 15485475
Drug: Oral methionine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral methionine, 100 mg kg(‐1) in fruit juice plus antioxidant vitamin E, 800 IU, and ascorbic acid, 1000 mg
Trial: 11568905
Drug: Vincristine administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vincristine administration
Trial: 9623632
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg paroxetine (T II)
Trial: 9623632
Drug: 21 g
RxNorm normalized name: Long's Lancets, 21 ga
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 21 g branched-chain amino acids (BCAA) (T III)
Trial: 9623632
Drug: 20 g
RxNorm normalized name: PEG-20 glyceryl oleate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 g tyrosine (TYR) (T IV)
Trial: 8209277
Drug: Adjuvant therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant therapy following surgical resection for stages I, II, and IIIA disease
Trial: 8209277
Drug: Induction chemotherapy
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction chemotherapy for locally advanced stages IIIA and IIIB disease
Trial: 8209277
Drug: Chemotherapy for
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy for advanced stage IV disease
Trial: 8209277
Drug: Biologic response
RxNorm normalized name: Besponsa
DrugBank: Inotuzumab ozogamicin (DB05889)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Biologic response modifiers (interferons, interleukins, colony-stimulating factors, monoclonal antibodies)
Trial: 21474786
Drug: Oral testosterone
RxNorm normalized name: testosterone Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral testosterone undecanoate (TU)
Trial: 24003041
Drug: Transdermal glyceryl
RxNorm normalized name: glyceryl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal glyceryl trinitrate (GTN; 5 mg/24 hours) for 7 days
Trial: 21410294
Drug: Vandetanib 300
RxNorm normalized name: vandetanib 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vandetanib 300 mg with rifampicin 600 mg/day (Study A)
Trial: 21410294
Drug: Vandetanib 300
RxNorm normalized name: vandetanib 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vandetanib 300 mg with itraconazole 200 mg/day (Study B)
Trial: 12511526
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg OD losartan (LOS)
Trial: 12511526
Drug: 80 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg OD telmisartan (TEL)
Trial: 12511526
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg OD losartan (LOS) + 20 mg OD lisinopril
Trial: 12511526
Drug: 80 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg OD telmisartan (TEL) + 20 mg OD lisinopril
Trial: 12511526
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg OD losartan (LOS)
Trial: 12511526
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg BID losartan (LOS)
Trial: 12511526
Drug: 160 mg
RxNorm normalized name: nadolol 160 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 160 mg OD telmisartan (TEL)
Trial: 12511526
Drug: 80 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg BID telmisartan (TEL)
Trial: 8927672
Drug: Sertraline (selective
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline (selective serotonin reuptake inhibitor)
Trial: 8927672
Drug: Imipramine (tricyclic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imipramine (tricyclic antidepressant)
Trial: 10934454
Drug: Soluble human
RxNorm normalized name: Recombinant soluble human CD4
DrugBank: Recombinant soluble human CD4 (DB17782)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soluble human insulin
Trial: 6348995
Drug: Inhalation of
RxNorm normalized name: Ocean brand of sodium chloride Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation of 200 micrograms salbutamol followed immediately by 100 micrograms beclomethasone dipropionate
Trial: 6348995
Drug: Inhalation of
RxNorm normalized name: Ocean brand of sodium chloride Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation of 200 micrograms salbutamol followed by 100 micrograms beclomethasone dipropionate after a timed interval of more than five minutes
Trial: 21562067
Drug: saxagliptin 5
RxNorm normalized name: sAXagliptin 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: saxagliptin 5 mg
Trial: 30653843
Drug: Lutikizumab 100
RxNorm normalized name: Lutikizumab
DrugBank: Lutikizumab (DB16224)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lutikizumab 100 mg
Trial: 30653843
Drug: Lutikizumab 25
RxNorm normalized name: Lutikizumab
DrugBank: Lutikizumab (DB16224)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lutikizumab 25 mg
Trial: 30653843
Drug: Lutikizumab 200
RxNorm normalized name: Lutikizumab
DrugBank: Lutikizumab (DB16224)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lutikizumab 200 mg
Trial: 30653843
Drug: Lutikizumab (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lutikizumab (all doses)
Trial: 30653843
Drug: Lutikizumab (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lutikizumab (100 mg)
Trial: 30463826
Drug: Systemic administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Systemic administration of methotrexate
Trial: 30463826
Drug: Local administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Local administration of methotrexate
Trial: 24905427
Drug: Exercise therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise therapy (ET) for 12 weeks (36 sessions)
Trial: 15157261
Drug: 500 mL
RxNorm normalized name: TPN Bag 500 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mL of water ingested 30 minutes before blood donation
Trial: 2742942
Drug: Haloperidol (HAL)
RxNorm normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Haloperidol (HAL) 10 mg oral test dose
Trial: 2742942
Drug: Haloperidol (HAL)
RxNorm normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Haloperidol (HAL) 5 mg orally twice daily for 7 days
Trial: 2742942
Drug: Reduced Haloperidol
RxNorm normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Reduced Haloperidol (RHAL) 10 mg oral test dose
Trial: 29223557
Drug: rosuvastatin 20
RxNorm normalized name: rosuvastatin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rosuvastatin 20 mg/d plus ω‐3 fatty acids 4 g/d (ROSUMEGA group)
Trial: 29223557
Drug: rosuvastatin 20
RxNorm normalized name: rosuvastatin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rosuvastatin 20 mg/d (rosuvastatin group)
Trial: 27769209
Drug: Family-based behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Family-based behavioral social facilitation treatment (FBSFT), 17 weekly sessions at the OOC.
Trial: 27769209
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (treatment as usual, TAU), monthly counselling sessions with primary health care nurse.
Trial: 18332845
Drug: Haloperidol 0.5
RxNorm normalized name: haloperidol 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haloperidol 0.5 mg TID, administered from up to 72 hours preoperatively until the third postoperative day
Trial: 12641541
Drug: Insulin lispro
RxNorm normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin lispro (0.2 Iu kg‐1) and vitamin C (1-g daily)
Trial: 1947866
Drug: Day treatment
RxNorm normalized name: Pharmacist Clotrimazole 3 Day Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Day treatment with community care
Trial: 27333261
Drug: ABC (brief
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABC (brief advice and subsidized nicotine replacement therapy)
Trial: 25148255
Drug: Warfarin induction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin induction therapy
Trial: 19914560
Drug: Surgery with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgery with adjuvant therapy
Trial: 19914560
Drug: Variations in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Variations in staging methods, surgical technique, radiotherapy technique, and chemotherapy regime
Trial: 17324220
Drug: Ginkgo biloba
RxNorm normalized name: Ginkgo Biloba
DrugBank: Ginkgo biloba (DB01381)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ginkgo biloba extract (EGb761) 240 mg
Trial: 15644624
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg moclobemide daily for 6 months
Trial: 29144805
Drug: Sitagliptin 100
RxNorm normalized name: SITagliptin 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sitagliptin 100 mg daily (SITA)
Trial: 18432391
Drug: Self-administered TLFB
RxNorm normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Self-administered TLFB
Trial: 18432391
Drug: Telephone-administered TLFB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telephone-administered TLFB
Trial: 14962967
Drug: Arthrographic distension
RxNorm normalized name: Disperse Blue 106
DrugBank: Disperse Blue 106 (DB14203)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arthrographic distension with saline and steroid
Trial: 12664761
Drug: Musculo‐skeletal medicine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Musculo‐skeletal medicine physician
Trial: 9409315
Drug: Fradafiban (dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fradafiban (dose producing > 80% fibrinogen receptor occupancy)
Trial: 6761186
Drug: Aspirin 330
RxNorm normalized name: aspirin 330 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin 330 mg
Trial: 8518408
Drug: Toremifene (TOR)
DrugBank: Toremifene (DB00539)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Toremifene (TOR) 240 mg/day
Trial: 8518408
Drug: Tamoxifen (TAM)
DrugBank: Tamoxifen (DB00675)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tamoxifen (TAM) 40 mg/day
Trial: 8518408
Drug: Second line
RxNorm normalized name: Gallus gallus gizzard lining preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Second line TOR or TAM treatment
Trial: 11560537
Drug: QI-therapy (n
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QI-therapy (n = 489 patients)
Trial: 30818320
Drug: Implant systems
RxNorm normalized name: Drug Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Implant systems with the same surface and different design
Trial: 26466947
Drug: Atorvastatin 40
RxNorm normalized name: atorvastatin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 40 mg add-on therapy to interferon β1b
Trial: 26466947
Drug: Placebo add-on
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo add-on therapy to interferon β1b
Trial: 17509693
Drug: 10-session, protocol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10-session, protocol continuation-phase therapy for 8 months
Trial: 17509693
Drug: Control cohort
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control cohort (stopped protocol treatment after the acute-phase)
Trial: 15129317
Drug: Cyclosporin alone
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporin alone (3.5 mg/kg/day) for three months
Trial: 15129317
Drug: Cyclosporin (3.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporin (3.5 mg/kg/day) plus topical calcipotriol cream twice a day for three months
Trial: 12472705
Drug: Midazolam 0.5
RxNorm normalized name: midazolam 0.5 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam 0.5 mg x kg(‐1) with ketamine 1.8 mg x kg(‐1) (MK‐1)
Trial: 12472705
Drug: Midazolam 0.5
RxNorm normalized name: midazolam 0.5 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam 0.5 mg x kg(‐1) with ketamine 3 mg x kg(‐1) (MK‐2)
Trial: 12472705
Drug: Midazolam 0.5
RxNorm normalized name: midazolam 0.5 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam 0.5 mg x kg(‐1) (MD)
Trial: 11748787
Drug: Olanzapine 5
RxNorm normalized name: olanzapine 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olanzapine 5 mg/day
Trial: 24613032
Drug: Olanzapine 15
RxNorm normalized name: olanzapine 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olanzapine 15 mg/day
Trial: 17022791
Drug: Olanzapine 20
RxNorm normalized name: olanzapine 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olanzapine 20 mg/day
Trial: 9659858
Drug: Olanzapine 30-40
RxNorm normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Olanzapine 30-40 mg/day
Trial: 9659858
Drug: Olanzapine 10-20
RxNorm normalized name: olanzapine 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olanzapine 10-20 mg/day
Trial: 9659858
Drug: Olanzapine 30
RxNorm normalized name: olanzapine 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olanzapine 30 mg/day and higher
Trial: 12212663
Drug: 0.2 mg
RxNorm normalized name: niacin 0.2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 mg clonidine
Trial: 12212663
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg yohimbine
Trial: 21775918
Drug: Infusion with
RxNorm normalized name: Pureline Basic Infusion with Butterfly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion with 20 mg of nafamostat mesilate (group B)
Trial: 21775918
Drug: Infusion with
RxNorm normalized name: Pureline Basic Infusion with Butterfly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion with 50 mg of nafamostat mesilate (group C)
Trial: 21775918
Drug: Nafamostat mesilate
RxNorm normalized name: mesylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nafamostat mesilate (20 mg) in low-risk patients
Trial: 21775918
Drug: Nafamostat mesilate
RxNorm normalized name: mesylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nafamostat mesilate (50 mg) in low-risk patients
Trial: 21775918
Drug: Nafamostat mesilate
RxNorm normalized name: mesylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nafamostat mesilate (20 mg) in high-risk patients
Trial: 21775918
Drug: Nafamostat mesilate
RxNorm normalized name: mesylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nafamostat mesilate (50 mg) in high-risk patients
Trial: 18620801
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of topiramate and amitriptyline
Trial: 16407642
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin C and E supplementation (500 mg slow-release vitamin C and 272 IU vitamin E for 4 weeks)
Trial: 16407642
Drug: Hyperbaric oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperbaric oxygen (HBO) treatment (100% O2, 2.4 bar, 131 min)
Trial: 14645636
Drug: Radiotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiotherapy with concurrent administration of cisplatin
Trial: 14645636
Drug: Radiotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiotherapy with concurrent cisplatin
Trial: 14645636
Drug: Concurrent radiotherapy
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Concurrent radiotherapy and cisplatin
Trial: 7060821
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg penbutolol
Trial: 7060821
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (propranolol or metoprolol with chlorthalidone)
Trial: 30830964
Drug: Morphine-3-glucuronide (M3G)
RxNorm normalized name: MENTHOL GLUCURONIDE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine-3-glucuronide (M3G)
Trial: 21041105
Drug: Morphine-6-glucuronide (M6G)
RxNorm normalized name: MENTHOL GLUCURONIDE
DrugBank: Morphine glucuronide (DB06409)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine-6-glucuronide (M6G)
Trial: 27989501
Drug: DFA-02 gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DFA-02 gel (gentamicin 16.8 mg/mL and vancomycin 18.8 mg/mL)
Trial: 27989501
Drug: DFA-02 gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DFA-02 gel
Trial: 11153970
Drug: Graded exposure
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Graded exposure in vivo treatment
Trial: 3371389
Drug: metoprolol CR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: metoprolol CR (100 mg)
Trial: 3371389
Drug: metoprolol SR
DrugBank: Metoprolol (DB00264)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: metoprolol SR (100 mg)
Trial: 27651514
Drug: HYD intact
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HYD intact 60 mg
Trial: 27651514
Drug: HYD chewed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HYD chewed 60 mg
Trial: 27651514
Drug: HYD milled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HYD milled to fine particles 60 mg
Trial: 27651514
Drug: Hydrocodone solution
RxNorm normalized name: hydrocodone Injectable Solution
DrugBank: Hydrocodone (DB00956)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydrocodone solution 60 mg
Trial: 27651514
Drug: Hydrocodone solution,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrocodone solution, HYD fine particles, HYD chewed, and HYD intact
Trial: 21427643
Drug: Cognitive behavior
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavior therapy (CBT), up to 10 sessions for 12 weeks
Trial: 17045826
Drug: Prednisolone (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisolone (10 mg bd)
Trial: 17045826
Drug: Cilomilast (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cilomilast (15 mg bd)
Trial: 9304515
Drug: Multimodality therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multimodality therapy (chemotherapy and irradiation)
Trial: 8492199
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg of methylprednisolone given intravenously before operation in combination with orally administered rapid‐release and sustained‐release diclofenac preparations
Trial: 2963645
Drug: Eleutherococcus senticosus
RxNorm normalized name: Eleutherococcus Senticosus Root
DrugBank: Eleuthero (DB14303)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eleutherococcus senticosus extract (10 ml, ethanolic preparation, 3 times daily for 4 weeks)
Trial: 3076791
Drug: Subcutaneous terbutaline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous terbutaline
Trial: 17127777
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of ipratropium bromide and salbutamol
Trial: 11391739
Drug: N‐0923 TDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N‐0923 TDS 33.5 mg
Trial: 11391739
Drug: N‐0923 TDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N‐0923 TDS 67 mg
Trial: 9164591
Drug: d-amphetamine 10
RxNorm normalized name: amphetamine / dextroamphetamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: d-amphetamine 10 mg in SOC